871 results about "Eye disease" patented technology

Methods of treating patients with chronic thyroid eye disease are provided for herein, such as by administering antibodies and compositions that bind to and / or antagonize IGF-1R.

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The invention provides an eye health state monitoring and evaluation method and device based on big data, and relates to the technical field of health monitoring, and the method comprises the steps: obtaining first information, second information and third information; performing three-dimensional reconstruction processing according to the first information to obtain three-dimensional eye feature data; performing pattern recognition processing according to the second information to obtain historical health feature data; performing time sequence analysis according to the historical health feature data and the third information to obtain behavior-environment cumulative effect data; performing data fusion processing according to the historical health feature data and the behavior-environment cumulative effect data, and obtaining potential risk data by predicting potential risk factors of child eye health; and performing evaluation processing according to the three-dimensional eye feature data and the risk data to obtain an evaluation result. According to the method, the modes and trends related to the specific eye diseases are recognized by using the big data mining and mode recognition technology, and potential health problems can be recognized in advance.

The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Described herein are methods of treating or reducing the severity of thyroid eye disease (TED), as well as antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1, useful in the methods.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

The invention provides an eye control interaction method, device and system based on eye movement tracking, and relates to the technical field of data processing. The method comprises the following steps: collecting eye movement data and user feature data of a testee; the user feature data comprises age, pupil color and eye disease type; extracting eye movement feature data according to the eye movement data and the user feature data; generating brain activity state information of the testee according to the eye movement feature data, and determining an eye control instruction of the testee according to the brain activity state information, the eye movement feature data and the user feature data; and performing eye control interaction based on the eye control instruction. According to the method, the characteristics of brain activity states, eye diseases and the like possibly existing in different types of users can be considered, the user feature data are collected, feature extraction is carried out in combination with the eye movement data, and the eye movement feature data accurately reflecting the real eye movement intention of the user is obtained, so that the obtained eye control instruction is adaptive to different users; while the eye control interaction accuracy is improved, smoother and more natural interaction experience is brought to the user.

The invention discloses a pair of intelligent eyesight monitoring and eye disease prediction glasses, and aims to solve the problems that most of existing eye health monitoring devices are used for regular inspection, cannot monitor and predict the eye health condition in real time and are difficult to take intervention measures in time, the glasses comprise glasses legs and a glasses main body, and the glasses main body is provided with an inner side facing a wearer; the glasses body further comprises a miniature camera, an optical sensor, a master control system and a battery system. The miniature camera is connected with the main control system through an application-specific integrated circuit, and the miniature camera is installed on the inner side of the glasses body facing the eyes of a wearer and used for shooting eye images of the wearer in real time and capturing the pupil size, eyeball movement and sight line direction of the wearer; the optical sensor is connected with the main control system and is used for detecting the ambient light intensity and color and adjusting the brightness of the lenses of the glasses main body; the eye health condition of the teenagers can be monitored and predicted in real time, and accurate health data support is provided for parents, teachers and ophthalmologists.

The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are also contemplated.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, a preparation method therefor and the use thereof. The compound (I) has a good TSHR antagonistic effect, and is used for treating thyroid-associated disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and for preparing drugs for such disorders or diseases.

The present invention relates to an ophthalmic knife and methods of its use for treatment of various conditions including eye diseases, such as glaucoma, using minimally invasive surgical techniques. The device is configured for cutting the tissues within the eye, for example, a trabecular meshwork (TM).

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition thereof and a use thereof. The compound provided by the present disclosure can be used for effectively treating PDE4-related diseases and disorders, including but not limited to inflammatory respiratory diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory skin diseases, inflammatory eye diseases, and diseases or cancers of the peripheral or central nervous system.

The invention discloses a multi-task learning-based retinal vessel segmentation and analysis method and system, and relates to the technical field of medical image processing, and the method comprises the steps: introducing an EMCAD module into an R-Unet model, and carrying out the retinal vessel segmentation; designing an area percentage quantization function; a multi-task learning framework RetiVas-MTNet is constructed and is used for auxiliary diagnosis of eye diseases. The EMCAD module fuses a channel attention CAB mechanism and a space attention SAB mechanism: 1) generating a channel weight through adaptive maximum pooling and average pooling, and strengthening key channel features; (2) context connection of local features is established through large kernel convolution, and the space attention weight is calculated; according to the invention, the EMCAD module is introduced, so that the segmentation precision of the microvessels is improved; the blood vessel area percentage is quantitatively designed, so that the crossing from qualitative segmentation to quantitative diagnosis is realized; a multi-task learning framework RetiVas-MTNet provides a comprehensive solution for automatic diagnosis of eye diseases.

The invention discloses a visual conversion system, method and equipment for eye disease auxiliary diagnosis and a storage medium, and solves the problems of single function, high data dependence, large computing resource demand and weak interpretability in the field of eye disease auxiliary diagnosis in the prior art. The system comprises an input processing module, a visual transformer trunk, a hybrid expert layer, a decoder head and an output generation module. According to the visual conversion system for eye disease auxiliary diagnosis, various ophthalmology imaging modes can be processed, multiple tasks can be executed, and the input processing module, the visual transformer trunk, the mixed expert layer, the decoder head and the output generation module in the system cooperate to reduce calculation requirements and maintain accuracy at the same time; the expert is dynamically selected according to the complexity of the input image, it is ensured that different inputs can obtain optimal feature processing, accuracy and efficiency are both considered, a decoder structure can be customized according to the features of different tasks, and the output precision of each task is ensured.

The invention discloses an eye disease diagnosis system and method based on a lesion space structure relation, and belongs to the technical field of intelligent eye disease diagnos.The eye disease diagnosis system comprises a lesion significance enhancement module and a lesion visual distribution information fusion module; the method comprises the following steps of: firstly, obtaining the characteristics of an eye lesion pixel, further refining the saliency characteristics to obtain the characteristics of the eye lesion pixel, constructing an eye lesion graph, and finally obtaining a global distribution mode of a lesion area through pooling operation to complete the diagnosis of the eye disease. According to the eye disease diagnosis system and method provided by the invention, effective information can be provided for identification and diagnosis of different types of eye diseases, an accurate retinal disease diagnosis result can be obtained, dispersed pathological features in the fundus image and a global distribution mode of the dispersed pathological features can be comprehensively understood, the calculation speed of a network is accelerated, and the calculation cost is reduced.

Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof for treating thyroid eye disease (TED) are provided herein. Anti-IGF-1R antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.

The present invention relates to a nucleic acid sequence derived from a regulatory region of a human Lgr5 gene and having promoter activity in retina non-long-process cells. The invention also relates to an expression cassette or vector comprising the promoter, a viral particle or cell comprising the expression cassette or vector, and a pharmaceutical composition comprising the expression cassette or vector and the viral particle or cell. The invention also relates to the use of the expression cassette, vector, viral particle, cell or pharmaceutical composition in the treatment of eye diseases, especially diseases associated with retinal ganglion cell degeneration.

The invention relates to an ophthalmic pharmaceutical composition which comprises or consists of the following components in parts by weight: 1 part of an active pharmaceutical ingredient, 0.95-1.25 parts of a liquid matrix and 0.35-0.45 part of a solid matrix, and the particle size D90 of the active pharmaceutical ingredient is less than or equal to 50 microns. The invention also relates to a preparation method of the ophthalmic medicine composition, an ophthalmic medicine box containing the ophthalmic medicine composition, and application of the ophthalmic medicine composition or the ophthalmic medicine box in preparation of medicines for preventing and / or treating eye diseases.

The present invention relates to an exogenous target gene expression cassette for delivering an exogenous target gene to the retina, in particular AIPL1 to retinal pigment epithelial cells and photoreceptor cells, comprising an IRBP enhancer sequence, a rhodopsin kinase (RK) promoter sequence and a CAG intron sequence, which are operatively linked, and an exogenous target gene. The present invention also relates to a recombinant adeno-associated viral vector comprising a viral capsid comprising a capsid protein or a capsid protein variant and a viral vector genome comprising an expression cassette encoding for specifically expressing an exogenous target gene in retinal pigment epithelial cells and photoreceptor cells. The recombinant adeno-associated virus vector can be used for relieving or treating retinal degenerative eye diseases by intravitreal administration or subretinal administration.

The present invention relates generally to compositions, formulations, and methods for immunotherapy and drug delivery, including the treatment of eye diseases such as dry eye disease (DED). In particular, the present invention relates to methods of producing exosomes from mesenchymal stem cells (MSC-Exos) and, optionally, loading said exosomes with one or more bioactive substances. The exosomes may be loaded using electroporation with one or more bioactive substances such as proteins, miRNAs, and / or siRNA. In specific embodiments, the exosomes, and / or one or more biological compounds derived from the exosomes, may be provided to an individual in need thereof, including as part of one or more compositions containing mesenchymal stem cells (MSCs). The individual in need thereof may be an individual having a medical disorder such as DED, immune disorders, cancer, and other disorders. Therefore, the compositions containing MSCs can be used for topical application to the eye. The compositions can contain MSCs, MSC-Exos, one or more MSC-derived biological compounds (e.g., growth factors, proteins, etc.).

The invention relates to the technical field of medicines, and provides a lanosterol derivative as well as a preparation method and application thereof. The lanosterol derivative provided by the invention has a structural formula as shown in a formula I or a formula II. The lanosterol derivative provided by the invention has both fat solubility and water solubility, and can effectively permeate into a diseased region in a body, so that the medicinal availability is improved; results of the embodiment show that the solubility of the lanosterol derivative provided by the invention in water is obviously higher than that of lanosterol or 25-hydroxylanosterol, and the lanosterol derivative shows an obvious cataract treatment effect in animal in-vivo experiments and has a wide prospect in preparation of drugs for treating eye diseases or symptoms. # imgabs0 #

The invention relates to a steroid compound and a pharmaceutical composition containing the steroid compound. The steroid compound has a structure as shown in a formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the structure as shown in the formula (I). The compound or the composition provided by the invention can be used for preparing medicines for preventing, treating, treating or relieving eye diseases of patients. # imgabs0 #

The present disclosure provides methods of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment. Further provided herein are pharmacologically active agents, compositions, methods and / or dosing schedules for the treatment of thyroid eye disease.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

The invention provides an eye disease prediction method and device, electronic equipment and a readable storage medium. The method comprises the following steps: acquiring an eye fundus image and an anterior segment optical coherence tomography image of the eyes of a user; inputting the fundus image and the anterior segment optical coherence tomography image into a trained eye disease prediction model to obtain an eye disease prediction result output by the trained eye disease prediction model; wherein the trained eye disease prediction model is used for extracting a first eye feature from the fundus image and extracting a second eye feature from the anterior segment optical coherence tomography image, fusing the first eye feature and the second eye feature to obtain an eye fusion feature, and outputting an eye disease prediction result according to the eye fusion feature. According to the method, the neural network obtains the complementary information of the multi-modal data, the eye disease is predicted according to the complementary information of the multi-modal data, and the accuracy of judging the eye disease risk is improved.